Provided herein is the identification of markers associated with THCV, THCVA, CBDV, CBDVA, CBGV, or CBGVA production in Cannabis plants and their use in selecting Cannabis plants having modified THCV, THCVA, CBDV, CBDVA, CBGV, or CBGVA activity. The markers are useful for breeding plants having modified varin activity, including elevated THCV levels, by obtaining nucleic acids, detecting one or more markers that indicate modified varin activity, and establishing plant lines having such characteristics.

The present invention relates to hemp products, such as sprouted hemp seed products, and methods for producing the same. The methods preserve the nutritional values of hemp seeds prior to processing.

A new cultivar of Cannabis plant named ‘MOC20P01’ that is characterized by about 1% THC and about 16% CBD by dry weight.

A new cultivar of Cannabis plant named ‘MOC20P01’ that is characterized by about 1% THC and about 16% CBD by dry weight.

Synthetic cannabinoid compounds for treatment of pain and anxiety by administering to an individual in need thereof a pharmaceutical composition including a compound having the structure:

##STR00001##

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle therefor.

A method of grading and processing hemp microgreens into a consumable hemp microgreen desiccant that includes the steps of first screening a plurality of hemp seeds for a predetermined manufacturing use that is based on a plurality of quantitative seed characteristics, separating the plurality of hemp seeds into a first and a second separated plurality of hemp seeds based on at least one of a plurality of organoleptic seed characteristics predicated on a standard for manufacturing high-grade hemp microgreens, cultivating a plurality of hemp microgreens with the first separated plurality of hemp seeds, then screening the plurality of hemp microgreens based on the above-described organoleptic characteristics to confirm the plurality of hemp seeds maintain grading standards. Thereafter, the hemp microgreens are separated into high-grade and low-grade microgreens, packaging the high-grade hemp microgreens into a container for fresh sale, and processing the low-grade hemp microgreens into a consumable hemp microgreen desiccant.

A method of grading and processing hemp microgreens into a consumable hemp microgreen desiccant that includes the steps of first screening a plurality of hemp seeds for a predetermined manufacturing use that is based on a plurality of quantitative seed characteristics, separating the plurality of hemp seeds into a first and a second separated plurality of hemp seeds based on at least one of a plurality of organoleptic seed characteristics predicated on a standard for manufacturing high-grade hemp microgreens, cultivating a plurality of hemp microgreens with the first separated plurality of hemp seeds, then screening the plurality of hemp microgreens based on the above-described organoleptic characteristics to confirm the plurality of hemp seeds maintain grading standards. Thereafter, the hemp microgreens are separated into high-grade and low-grade microgreens, packaging the high-grade hemp microgreens into a container for fresh sale, and processing the low-grade hemp microgreens into a consumable hemp microgreen desiccant.

A method of producing cannabinoids for use in medical treatments by growing cultured Cannabis sativa plant cells through tissue culture, the method of comprising the steps of: selecting Cannabis sativa leaf tissue for culture; and growing a tissue culture from the selected leaf tissue in a liquid based medium whilst controlling the light exposure of the tissue culture to control the cannabinoid content of the tissue culture. Control of the light exposure can enable the phytocannabinoid content of the grown tissue culture to be tailored to the use intended for the tissue culture. For example, the THC content of the tissue culture can be controlled to be maximised or minimized depending on the intended use. Use of tissue culture is beneficial as compared to prior art methods as it allows for genetic consistency and reduces the resources necessary to produce plant cells containing phytocannabinoids.

A method of producing cannabinoids for use in medical treatments by growing cultured Cannabis sativa plant cells through tissue culture, the method of comprising the steps of: selecting Cannabis sativa leaf tissue for culture; and growing a tissue culture from the selected leaf tissue in a liquid based medium whilst controlling the light exposure of the tissue culture to control the cannabinoid content of the tissue culture. Control of the light exposure can enable the phytocannabinoid content of the grown tissue culture to be tailored to the use intended for the tissue culture. For example, the THC content of the tissue culture can be controlled to be maximised or minimized depending on the intended use. Use of tissue culture is beneficial as compared to prior art methods as it allows for genetic consistency and reduces the resources necessary to produce plant cells containing phytocannabinoids.

The invention provides compositions and methods for the breeding, production, processing and use of specialty Cannabis.